Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2954 • 2015 ACR/ARHP Annual Meeting
Serum and CSF Biomarkers of Neuropsychiatric Involvement in Primary Sjogren Syndrome and Systemic Lupus Erythematosus
Maria Boge Lauvsnes¹, Anne Bolette Tjensvoll², Ingeborg Kvivik³, Roald Omdal⁴ and Chaim Putterman⁵, ¹Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ²Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ³Reasearch Department, Stavanger University Hospital, Stavanger, Norway, ⁴Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁵Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric manifestations are commonly observed in both SLE and primary Sjšgren's syndrome (pSS). However, making an accurate diagnosis can be challenging. Multiple serum and…
Abstract Number: 625 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease
Frederick B Vivino¹, Steven E. Carsons², Ann Parke³, Nancy Carteron⁴, Vidya Sankar⁵, Richard Brasington⁶, Robert Fox⁷, William Ehlers³, Michael Brennan⁸, Robert Hal Scofield⁹, Katherine M Hammitt¹⁰ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Allergy and Immunology, Winthrop University Hospital, Mineola, NY, ³University of Connecticut, Farmington, CT, ⁴University of California, San Francisco, CA, ⁵Univeristy of Texas, San Antonio, TX, ⁶Washington University, St Louis, MO, ⁷Rheumatology Clinic, La Jolla, CA, ⁸Carolinas Medical Center, Charlotte, NC, ⁹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ¹⁰Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD
Background/Purpose: There are currently no FDA approved immunomodulating agents available for treatment of the extraglandular manifestations of Sjogren’s (SS). Clinical practice guidelines were developed for…
Abstract Number: 647 • 2015 ACR/ARHP Annual Meeting
Involvement of Peripheral Nervous System in Primary Sjögren Syndrome, a Gessar Analysis
M. Mayer¹, S. Velez², F. Zazzetti², J. C. Barreira², L. Galvan¹, G. Bennasar³, L. R. Carlevaris³, A. Secco³, C. Asnal⁴, P. Pucci⁴, C. Amitrano⁴, A. Nitsche⁴, M. C. Khoury⁵, F. Caeiro⁶, N. Benzaquén⁶, J.P. Pirola⁶, M. Colazo⁶, O.L. Rillo⁷, S. Papasidero⁷, J. Demarchi⁷, L. Raitti⁸, M. N. Tamborenea⁹, M. L. Santiago⁹, P. Alba¹⁰, B. Busamia¹⁰, G. Salvatierra¹¹ and A. Catalán Pellet³, ¹Rheumatology, Buenos Aires British Hospital, CABA, Argentina, ²Rheumatology, Buenos Aires British Hospital, Buenos Aires, Argentina, ³Rivadavia Hospital, CABA, Argentina, ⁴German Hospital, CABA, Argentina, ⁵Statistics, Buenos Aires British Hospital, CABA, Argentina, ⁶Private Hospital of Cordoba, Cordoba, Argentina, ⁷Tornú Hospital, CABA, Argentina, ⁸Bessone Clinic, CABA, Argentina, ⁹OMI, Buenos Aires, CABA, Argentina, ¹⁰Córdoba Hospital, Cordoba, Argentina, ¹¹IPRI, Santiago del Estero, Santiago del Estero, Argentina
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by dysfunction of the exocrine glands. The frequency of neurological manifestations in pSS ranges from…
Abstract Number: 2282 • 2015 ACR/ARHP Annual Meeting
“Doing Every-Day Life” with Primary Sjögren’s Syndrome: Factors Predicting Difficulties Performing Daily Activities and Taking on Life Roles
Katie Hackett¹, Dennis W Lendrem², Tim Rapley³, Katherine Deane⁴, Vincent Deary⁵, Simon Bowman⁶, Julia Newton⁷, Wan-Fai Ng⁸ and on behalf of the United Kingdom Primary Sjogren's Syndrome Registry, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ³Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴University of East Anglia, Norwich, United Kingdom, ⁵School of Health Psychology, Northumbia University, Newcastle upon Tyne, United Kingdom, ⁶Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ⁷Newcastle University, Newcastle upon Tyne, United Kingdom, ⁸Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s Syndrome (pSS) is an autoimmune disease which targets secretory glands and results in dryness. In addition pSS patients frequently experience symptoms of…
Abstract Number: 3200 • 2015 ACR/ARHP Annual Meeting
Characterization of Early and Progressive Autoimmunity in Sjogrens Syndrome: The Incomplete Sjogrens Syndrome Model
Astrid Rasmussen¹, Christopher J Lessard², Indra Adrianto¹, Graham B. Wiley¹, Donald U Stone^3,4, C. Erick Kaufman⁵, Lida Radfar⁶, David M. Lewis⁷, Stephen K Young⁸, Michael H. Weisman⁹, Daniel J Wallace¹⁰, Swamy Venuturupalli¹¹, Barbara M. Segal¹², John A. Ice¹, Juan-Manuel Anaya¹³, Michael D. Rohrer¹⁴, Raj Gopalakrishnan¹⁵, Glen D Houston¹⁶, James Chodosh¹⁷, Pamela J Hughes¹⁸, Nelson L. Rhodus¹⁹, Jennifer A. Kelly²⁰, Kiely Grundahl²¹, Kimberly Hefner²², R. Hal Scofield^1,23,24 and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁴Department of Ophthalmology, Johns Hopkins University, Riyadh, Saudi Arabia, ⁵College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁷College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹³Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹⁴Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ¹⁵Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ¹⁶Heartland Pathology, Oklahoma City, OK, ¹⁷Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹⁸Division of Oral and Maxillofacial Surgery, University of Minnesota, Minneapolis, MN, ¹⁹Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁰Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ²²Hefner Eye Care and Optical Center, Oklahoma City, OK, ²³Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁴US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Autoimmune diseases are often preceded by subclinical serologic and functional abnormalities that predate diagnosis by several years. The insidious and progressive nature of these…
Abstract Number: 626 • 2015 ACR/ARHP Annual Meeting
Efficacy of Belimumab and Targeting of Rheumatoid Factor Positive B-Cells in Sjögren’s Syndrome: Follow-up of the Open-Label Phase II Study
Luca Quartuccio¹, Sara Salvin², Laura Corazza¹, Saviana Gandolfo², Martina Fabris³ and Salvatore De Vita⁴, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Rheumatology Clinic, University of Udine, Udine, Italy, ³Clinic of Rheumatology, University of Udine, Udine, Italy, ⁴Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy
Background/Purpose: Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody is preliminary found to be effective in Sjögren’s syndrome (SS) patients with moderate to high systemic…
Abstract Number: 648 • 2015 ACR/ARHP Annual Meeting
Klinefelter’s Syndrome (47,XXY) Among Men with Sjögren’s Syndrome
Valerie M Harris¹, Joshua Cavett², Biji Kurien³, Ke Liu⁴, Kristi A. Koelsch⁵, Lida Radfar⁶, David M. Lewis⁷, Donald U. Stone⁸, Shibo Li⁹, Barbara Segal¹⁰, Daniel J Wallace¹¹, Michael H. Weisman¹², Jennifer A. Kelly¹³, Marta Alarcon-Riquelme¹⁴, Bernado Pons-Estel¹⁵, Roland Jonsson¹⁶, Xianglan Lu⁹, Jacques Gottenberg¹⁷, Juan-Manuel Anaya¹⁸, Deborah S. Cunninghame-Graham¹⁹, Edward C. Keystone²⁰, Andrew J.W. Huang²¹, Michael T. Brennan²², Pamela Hughes²³, G Illei²⁴, Corinne Miceli²⁵, VP Bykerk²⁶, Gideon Hirschfield²⁷, Gang Xie²⁸, Wan-Fai Ng²⁹, Gunnel Nordmark³⁰, Per Eriksson³¹, Roald Omdal³², Nelson L. Rhodus³³, Maureen Rischmueller³⁴, Michael D. Rohrer³⁵, Marie Wahren-Herlenius³⁶, Torsten Witte³⁷, Xavier Mariette³⁸, Christopher Lessard³⁹, John B. Harley⁴⁰, Kathy L. Sivils³⁹ and Robert Hal Scofield⁴¹, ¹Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴3333 Burnet Ave., University of Cincinnati & Cincinnati Childre, Cincinnati, OH, ⁵Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁷College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁹Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Rheumatology, Univ of Minnesota, Minneapolis, MN, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹³Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Arthritis & Clinical Immunology, Oklahoma Medical REsearch Foundtion, Oklahoma City, OK, ¹⁵Hospital Provincial de Rosario, Rosario, Argentina, ¹⁶Broegelmann research laboratory, Bergen, Norway, ¹⁷Hautepierre, Strasbourg, France, ¹⁸Cell Biol and Immunogenetics, CIB-Rosario University, Medellin, Colombia, ¹⁹Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ²⁰Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²¹Department of Ophthalmology and Visual Sciences, Washington University, St Louis, MO, ²²Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ²³Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁴Sjögren's Clinic, NIDCR/NIH, Bethesda, MD, ²⁵Rheumatology, PARIS, France, ²⁶University of Toronto, Toronto, ON, Canada, ²⁷Centre for Liver Research, Institute of Biomedical Research, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ²⁸Mount Sinai Hospital, Toronto, ON, Canada, ²⁹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³⁰Medical Sciences, Uppsala University, Uppsala, Sweden, ³¹University Hospital, Rheumatology clinic, Linköping, Sweden, ³²Department of internal medicine, Clinical Immunology unit, Stavanger, Norway, ³³Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁴Rheumatology, Queen Elizabeth Hospital, Adelaide, Australia, ³⁵Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁶Department of Medicine, Experimental Rheumatology Unit, Solna, Sweden, ³⁷Department of Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ³⁸Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ³⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴⁰Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴¹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Primary Sjögren’s syndrome (pSS) has a strong female bias of greater than 10 to 1. This difference in risk of disease between the sexes…
Abstract Number: 2516 • 2015 ACR/ARHP Annual Meeting
Association Between Primary Sjögren’s Syndrome and Pregnancy Outcome: A Systematic Review and Meta-Analysis
Sikarin Upala¹ and Anawin Sanguankeo², ¹Internal Medicine, Bassett Medical Center, Cooperstown, NY, ²Bassett Medical Center, Cooperstown, NY
Background/Purpose: Systemic autoimmune disorders may interfere with normal reproductive function resulting in negative outcome of pregnancy. Primary Sjögren's syndrome (pSS) is a common rheumatic disease…
Abstract Number: 3201 • 2015 ACR/ARHP Annual Meeting
IL-7 Drives Cytokine Secretion of IL-7Rabright CCR9-Expressing T-Follicular Helper-like Cells: Potential New Axis in Lymphoid Neogenesis in Salivary Glands of Primary Sjogren s Syndrome Patients
S.L.M. Blokland^1,2, M.R. Hillen^1,2, A.A. Kruize¹, A. Kislat³, S. Meller³, B. Homey³, G.M. Smithson⁴, J. Zalevsky⁵, T.R.D.J. Radstake^1,2 and J.A.G. van Roon^1,6, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Dermatology, University of Düsseldorf, Medical Faculty, Düsseldorf, Germany, ⁴Takeda Pharmaceuticals International, Chicago, IL, ⁵Takeda California, San Diego, CA, ⁶Laboratory for Translational immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: In primary Sjögren’s syndrome (pSS) B cell hyperactivity including autoantibody secretion and lymphoma development are hallmark immunopathological features. Specific lymphoid organization (including germinal centers)…
Abstract Number: 526 • 2014 ACR/ARHP Annual Meeting
A Descriptive and Comparative Study of the Transcriptome from Salivary Exosomes of Sjögren’s Syndrome Patients Using RNA-Seq
Alessia Gallo¹, Mayank Tandon², Shyh-Ing Jang³, Ana Paola Cotrim⁴ and Ilias Alevizos⁵, ¹NIH, Bethesda, MD, ²Sjogren's Clinic, NIDCR, Bethesda, MD, ³Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ⁴NIDCR, NIH, Bethesda, MD, ⁵Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose Saliva is a biofluid secreted by the salivary glands (SGs) that is critical for the health of the oral cavity. In Sjögren’s Syndrome (SS),…
Abstract Number: 2929 • 2014 ACR/ARHP Annual Meeting
Molecular Diagnostics for Patient Subsetting in Sjögren’s Syndrome
John C. Hall¹, Alan N. Baer¹, Mi Y. Lam², Lindsey A. Criswell³, Antony Rosen¹ and Livia Casciola Rosen¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Orofacial Sciences, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose Sjögren’s syndrome (SS) is a chronic autoimmune disease which targets exocrine glands, particularly salivary and lacrimal glands. While all SS patients have abnormal secretory…
Abstract Number: 2543 • 2014 ACR/ARHP Annual Meeting
Anti-Ro/SSA Positive Incomplete Sjögren’s Syndrome
R. Hal Scofield¹, Anne Igoe², Donald U Stone³, Lida Radfar⁴, Kimberly S. Hefner⁵, David M. Lewis⁶, Stephen Young⁶, Judy Harris⁷, Kiely Grundahl⁷, Biji T. Kurien⁸, Jacen Maier-Moore⁹, Kristi A. Koelsch¹⁰, James Chodosh¹¹, Nelson L. Rhodus¹², Raj Gopalakrishnan¹³, Barbara M. Segal¹⁴, A. Darise Farris¹⁵, Courtney G. Montgomery¹⁶, Christopher J. Lessard¹⁷, Kathy L. Sivils¹⁸ and Astrid Rasmussen⁷, ¹US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²Metro Health, Cleveland, OH, ³Dean McGee Eye Institute, Oklahoma City, OK, ⁴College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁹Dept. of Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, ¹⁰Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ¹¹Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹²University of Minnesota, Minneapolis, MN, ¹³Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁷825 N.E. 13th St., Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a systemic disease characterized by dry eyes and mouth resulting from immune mediated damage and dysfunction of the lacrimal and…
Abstract Number: 525 • 2014 ACR/ARHP Annual Meeting
The Genetic Basis of Sjögren’s Syndrome (SS) Clinical Manifestations from Genome-Wide Association Analysis of Subphenotype Extremes in an International Cohort
Lindsey A. Criswell¹, Kimberly E. Taylor^2,3, Quenna Wong⁴, David M. Levine⁴, Caitlin McHugh⁴, Cathy Laurie⁴, Kimberly Doheny⁵, Mi Y. Lam⁶, Alan N. Baer⁷, Stephen Challacombe⁸, Yi Dong⁹, Hector Lanfranchi¹⁰, Morten Schiødt¹¹, M. Srinivasan¹², Susumu Sugai¹³, Hisanori Umehara¹⁴, Frederick B. Vivino¹⁵, Zhao Yan¹⁶, Stephen Shiboski¹⁷, Troy Daniels¹⁸, John S. Greenspan⁶, Caroline H. Shiboski⁶ and Sjögren's Syndrome Collaborative Clinical Alliance (SICCA)¹⁹, ¹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴University of Washington, Biostatistics, Seattle, WA, ⁵Center for Inherited Disease Research, Baltimore, MD, ⁶Orofacial Sciences, University of California San Francisco, San Francisco, CA, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Kings College London, London, United Kingdom, ⁹Dept of Rheumatology, Peking Univ Med Coll Hospital, East City Beijing, China, ¹⁰University of Buenos Aires, Buenos Aires, Argentina, ¹¹Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen, Denmark, ¹²Aravind Eye Hospital, Madurai, India, ¹³Kanazawa Medical University, Ishikawa, Japan, ¹⁴Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan, ¹⁵Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, ¹⁶Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ¹⁷Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, ¹⁸Orofacial Sciences, Box 0422, University of California San Francisco, San Francisco, CA, ¹⁹University of California San Francisco, San Francisco, CA
Background/Purpose Our goal is to define the contribution of genetic factors to two hallmark manifestations of SS, keratoconjunctivitis sicca (KCS) and focal lymphocytic sialadenitis (FLS),…
Abstract Number: 2932 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren’s Syndrome: A General Population-Based Cohort Study
Marko Yurkovich¹, Hyon K. Choi², Eric C. Sayre³, Kamran Shojania⁴ and J. Antonio Avina-Zubieta⁵, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: There is limited data available on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in Sjögren's Syndrome (SjS). We estimated the…
Abstract Number: 2541 • 2014 ACR/ARHP Annual Meeting
Autoantibodies in Pediatric Sjogren’s Patients
Lakshmanan Suresh¹, Minako Tomiita², Akira Hoshioka³, Long Shen⁴, Kishore Malyavantham⁵ and Julian Ambrus⁶, ¹60 Pineview Drive, State University of New York/Buffalo, Buffalo, NY, ²Department of Allergy and Rheumatology, Chiba Children’s Hospital, Chiba, Japan, ³Department of Allergy and Rheumatology,, Chiba Children’s Hospital,, Chiba, Japan, ⁴Department of Medicine, SUNY at Buffalo, Buffalo, NY, ⁵Research and Development, IMMCO Diagnostics Inc ., Amherst, NY, ⁶100 High St., University Of Buffalo, Buffalo, NY
Background/Purpose Sjogren’s syndrome (SS) is a common autoimmune disease involving the salivary and lacrimal glands along with various other organs. It is generally seen in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].